This Article Full Text Full Text (PDF) All Versions of this Article: 36/9/1915    most recent 01.STR.0000177874.29849.f0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Efstathiou, S. P. Articles by Mountokalakis, T. D. Search for Related Content PubMed PubMed Citation Articles by Efstathiou, S. P. Articles by Mountokalakis, T. D. Related Collections Acute Cerebral Infarction Related Article

(Stroke. 2005;36:1915.)
© 2005 American Heart Association, Inc.

Original Contributions

Plasma Adiponectin Levels and Five-Year Survival After First-Ever Ischemic Stroke

Stamatis P. Efstathiou, MD; Dimitrios I. Tsioulos, MD; Aphrodite G. Tsiakou, MD; Yannis E. Gratsias, MSc, BSc; Angelos V. Pefanis, MD Theodore D. Mountokalakis, MD

From the Center for the Prevention of Cardiovascular Disease (S.P.E., Y.E.G., T.D.M.), "Hygieias Melathron," Athens, Greece; Internal Medicine Department (D.I.T.), Metropolitan Hospital, Pireus, Greece; and Third University Department of Medicine (A.G.T., A.V.P.), Medical School, Sotiria General Hospital, Athens, Greece.

Correspondence to Stamatis P. Efstathiou, MD, 19 Fidiou St, Athens 15562, Greece. E-mail sefstath{at}tellas.gr

Background and Purpose— This study aimed to investigate the association between plasma adiponectin levels and 5-year survival after first-ever ischemic stroke.

Methods— Plasma adiponectin measured within 24 hours after first-ever ischemic stroke was related to 5-year outcome. The Kaplan–Meier technique was applied in survival analysis, and the Cox proportional hazards model was used to evaluate the relationship between risk factors and prognosis.

Results— The probabilities of death were 92.8%, 52.5%, and 10.5% (P<0.001) for patients stratified according to tertiles of adiponectin (<4 µg/mL, 4 to 7 µg/mL, and >7 µg/mL, respectively). The relative risk of death was 8.1 (95% CI, 3.1, 24.5; P<0.001) for individuals with adiponectin levels in the lowest tertile compared with the upper tertile. Adiponectin <4 µg/mL (hazard ratio [HR], 5.2; 95% CI, 2.1, 18.4; P<0.001), score >15 in the National Institutes of Health Stroke Scale (HR, 3.6; 95% CI, 1.7, 15.9; P<0.001), and coronary heart disease (HR, 2.9; 95% CI, 1.5, 12.3; P<0.001) were independently associated with mortality.

Conclusions— Low plasma adiponectin is related to an increased risk of 5-year mortality after first-ever ischemic stroke, independently of other adverse predictors.

Key Words: prognosis • stroke, ischemic • survival

Related Article:

Adiponectin: Spectator or Player?

Wayne M. Clark
Stroke 2005 36: 1919-1920. [Full Text] [PDF]

This article has been cited by other articles:

				E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]

				J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				M. Nishimura, Y. Izumiya, A. Higuchi, R. Shibata, J. Qiu, C. Kudo, H. K. Shin, M. A. Moskowitz, and N. Ouchi Adiponectin Prevents Cerebral Ischemic Injury Through Endothelial Nitric Oxide Synthase Dependent Mechanisms Circulation, January 15, 2008; 117(2): 216 - 223. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, T. Tanaka, H. Sakai, C. Ishikawa, M. Fujii, T. Yamamoto, and M. Horie Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure Eur. Heart J., July 2, 2007; 28(14): 1723 - 1730. [Abstract] [Full Text] [PDF]

				M. P. Santini, L. Tsao, L. Monassier, C. Theodoropoulos, J. Carter, E. Lara-Pezzi, E. Slonimsky, E. Salimova, P. Delafontaine, Y.-H. Song, et al. Enhancing Repair of the Mammalian Heart Circ. Res., June 22, 2007; 100(12): 1732 - 1740. [Abstract] [Full Text] [PDF]

				O. Y. Bang, J. L. Saver, B. Ovbiagele, Y. J. Choi, S. R. Yoon, and K. H. Lee Adiponectin levels in patients with intracranial atherosclerosis Neurology, May 29, 2007; 68(22): 1931 - 1937. [Abstract] [Full Text] [PDF]

				P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]

				S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]

				R. Wolk, P. Berger, R. J. Lennon, E. S. Brilakis, D. E. Davison, and V. K. Somers Association between plasma adiponectin levels and unstable coronary syndromes Eur. Heart J., February 1, 2007; 28(3): 292 - 298. [Abstract] [Full Text] [PDF]

				G. A. Laughlin, E. Barrett-Connor, S. May, and C. Langenberg Association of Adiponectin with Coronary Heart Disease and Mortality: The Rancho Bernardo Study Am. J. Epidemiol., January 15, 2007; 165(2): 164 - 174. [Abstract] [Full Text] [PDF]

				S. Pilz, H. Mangge, B. Wellnitz, U. Seelhorst, B. R. Winkelmann, B. Tiran, B. O. Boehm, and W. Marz Adiponectin and Mortality in Patients Undergoing Coronary Angiography J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4277 - 4286. [Abstract] [Full Text] [PDF]

				A. Chamorro and J. Hallenbeck The Harms and Benefits of Inflammatory and Immune Responses in Vascular Disease Stroke, February 1, 2006; 37(2): 291 - 293. [Full Text] [PDF]

				W. M. Clark Adiponectin: Spectator or Player? Stroke, September 1, 2005; 36(9): 1919 - 1920. [Full Text] [PDF]